Folic acid reduces doxorubicin‐induced cardiomyopathy by modulating endothelial nitric oxide synthase

The use of doxorubicin (DOXO) as a chemotherapeutic drug has been hampered by cardiotoxicity leading to cardiomyopathy and heart failure. Folic acid (FA) is a modulator of endothelial nitric oxide (NO) synthase (eNOS), which in turn is an important player in diseases associated with NO insufficiency...

Descripción completa

Detalles Bibliográficos
Autores principales: Octavia, Yanti, Kararigas, Georgios, de Boer, Martine, Chrifi, Ihsan, Kietadisorn, Rinrada, Swinnen, Melissa, Duimel, Hans, Verheyen, Fons K., Brandt, Maarten M., Fliegner, Daniela, Cheng, Caroline, Janssens, Stefan, Duncker, Dirk J., Moens, An L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706529/
https://www.ncbi.nlm.nih.gov/pubmed/28608983
http://dx.doi.org/10.1111/jcmm.13231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706529/
https://www.ncbi.nlm.nih.gov/pubmed/28608983
http://dx.doi.org/10.1111/jcmm.13231

Ejemplares similares